心衰患者去甲肾上腺素转运体基因启动子区甲基化水平与预后的关联研究

A Study of the Correlation Between the Methylation Level of Promoter Region of Norepinephrine Transporter Gene and Prognosis in Patients with Heart Failure

目的讨论心衰患者去甲肾上腺素转运体(NET,SLC6A2)基因启动子区甲基化水平与预后的关联。方法收集随访患者死亡预后信息,并根据预后将155例受试对象分为死亡预后组和存活预后组,分别包含31例和124例患者。研究针对去甲肾上腺素转运体(NET,SLC6A2)基因启动子区甲基化水平与患者预后的关联展开分析和讨论。结果随访中检出预后死亡患者31例,同124例预后存活的受试对象比较;预后死亡的受试对象吸烟史和饮酒史的患者比例显著高于预后存活组,P<0.05。本研究借助软件计算出4个片段位点甲基化率,焦磷酸测序图DNA中R或Y对应4个片段序列中CG中的C,T对应的是非CG的C。预后死亡组总甲基化率高于预后存活患者。总MTI是心衰死亡预后的危险因素,会使死亡风险增高2.99倍,P<0.05;此外,年龄的增加、既往吸烟和饮酒史以及DBP高,也表现为预后死亡的危险因素。结论 SLC6A2基因启动子区总甲基化的存在与心衰患者预后出现死亡存在正关联,总MTI是心衰死亡预后的危险因素,会使死亡风险增高。

Objective To investigate the association between the methylation level of promoter region of norepinephrine transporter（ NET, SLC6A2） and prognosis in patients with heart failure. Methods According to the prognosis, 105 subjects were divided into death prognosis group and survival prognosis group, including 31 patients and 124 patients respectively. The aim of this study is to analyze and discuss the relationship between methylation level of promoter region of norepinephrine transporter（ NET, SLC6A2 ） and prognosis of patients. SPSS software was used for data analysis. Results In our study, 31 patients with prognosis were detected during follow-up, compared with 124 patients with prognosis. The proportion of patients with smoking history and alcohol consumption in prognosis was significantly higher than that in prognosis survival group （P 〈 0. 05 ）. In this study, we calculated the methylation rate of four loci by software. The pyrosequencing DNA contained C or C in four segments of R or Y corresponding to non CG CG. The total methylation rate in the death group was higher than that in the prognosis survival group. Total MIT was a risk factor for the prognosis of HF, which increased the risk of death by 2.99 times （ P 〈 0.05 ）. In addition, the increased age, previous smoking and drinking history, and high DBP were also showed as risk factors for prognosis. Conclusion The presence of total methylation in SLC6A2 gene promoter region is positively correlated with the prognosis of HF patients. The overall MIT is a risk factor for the prognosis of HF, leading to an increased risk of death.